

## Special Issue

# Progress in the Pathogenesis, Diagnosis and Treatment of Chronic Kidney Disease

### Message from the Guest Editor

Chronic kidney disease is a public health issue of growing importance worldwide because of its impact on both individual morbidity and mortality and its economic burden for healthcare systems. In recent years, our understanding of its pathogenesis has developed, in terms of deciphering its molecular and cellular pathways of progression. Consequently, breakthrough research on new diagnosis biomarkers means that the early recognition of this condition is being promoted. From the "omics" approach which have shed insights into some of these aspects to biomarkers which are readily available in the daily medical practice and the contribution of artificial intelligence, the field is almost endless. In this Special Issue, we will collate the most essential knowledge from various research centers, focused on the theoretical background or experimental and clinical studies of the pathogenesis, diagnosis and treatment of chronic kidney disease. This can provide a useful tool for medical practitioners, medical students and future researchers in this scientific field.

---

### Guest Editor

Dr. Cristina Capusa

Nephrology Dept. at the "Dr. Carol Davila" Teaching Hospital of Nephrology, "Carol Davila" University of Medicine and Pharmacy, 010731 București, Romania

---

### Deadline for manuscript submissions

closed (30 June 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/121514](https://mdpi.com/si/121514)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).